Abstract
The derangement of the cardiac energy substrate metabolism plays a key role in the pathogenesis of heart failure. The utilization of non-carbohydrate substrates, such as fatty acids, is the predominant metabolic pathway in the normal heart, because this provides the highest energy yield per molecule of substrate metabolized. In contrast, glucose becomes an important preferential substrate for metabolism and ATP generation under specific pathological conditions, because it can provide greater efficiency in producing high energy products per oxygen consumed compared to fatty acids. Manipulations that shift energy substrate utilization away from fatty acids toward glucose can improve the cardiac function and slow the progression of heart failure. However, insulin resistance, which is highly prevalent in the heart failure population, impedes this adaptive metabolic shift. Therefore, the acceleration of the glucose metabolism, along with the restoration of insulin sensitivity, would be the ideal metabolic therapy for heart failure. This review discusses the therapeutic potential of modifying substrate utilization to optimize cardiac metabolism in heart failure.
Keywords: myocardial glucose and fatty acid metabolism, insulin resistance, metabolic therapy, heart failure, ATP generation, cardiomyocytes, TCA cycle, pyruvate oxidation, glycolysis, ROS formation
Current Pharmaceutical Design
Title: Optimization of Cardiac Metabolism in Heart Failure
Volume: 17 Issue: 35
Author(s): Tomohisa Nagoshi, Michihiro Yoshimura, Giuseppe M. C. Rosano, Gary D. Lopaschuk and Seibu Mochizuki
Affiliation:
Keywords: myocardial glucose and fatty acid metabolism, insulin resistance, metabolic therapy, heart failure, ATP generation, cardiomyocytes, TCA cycle, pyruvate oxidation, glycolysis, ROS formation
Abstract: The derangement of the cardiac energy substrate metabolism plays a key role in the pathogenesis of heart failure. The utilization of non-carbohydrate substrates, such as fatty acids, is the predominant metabolic pathway in the normal heart, because this provides the highest energy yield per molecule of substrate metabolized. In contrast, glucose becomes an important preferential substrate for metabolism and ATP generation under specific pathological conditions, because it can provide greater efficiency in producing high energy products per oxygen consumed compared to fatty acids. Manipulations that shift energy substrate utilization away from fatty acids toward glucose can improve the cardiac function and slow the progression of heart failure. However, insulin resistance, which is highly prevalent in the heart failure population, impedes this adaptive metabolic shift. Therefore, the acceleration of the glucose metabolism, along with the restoration of insulin sensitivity, would be the ideal metabolic therapy for heart failure. This review discusses the therapeutic potential of modifying substrate utilization to optimize cardiac metabolism in heart failure.
Export Options
About this article
Cite this article as:
Nagoshi Tomohisa, Yoshimura Michihiro, M. C. Rosano Giuseppe, D. Lopaschuk Gary and Mochizuki Seibu, Optimization of Cardiac Metabolism in Heart Failure, Current Pharmaceutical Design 2011; 17 (35) . https://dx.doi.org/10.2174/138161211798357773
DOI https://dx.doi.org/10.2174/138161211798357773 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design ACE2 and Diabetic Complications
Current Pharmaceutical Design Acute Actions of Natriuretic Peptides in Coronary Vasculature and Ischaemic Myocardium
Current Pharmaceutical Design Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Biology of Cholesterol Lowering in Atherosclerotic Plaques
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial (Thematic Issue: New Horizon in the Treatment of Hypertension - Role for Ca Channel Blockers - Why do Ca Channel Blockers be Focused on?)
Current Hypertension Reviews Pharmacogenetics of Antihypertensive Therapies: Can this be Applied in the Clinic?
Current Pharmacogenomics and Personalized Medicine Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Current Drug Targets The Optimal Treatment of Thyroid Gland Function Disturbances During Pregnancy
Current Pharmaceutical Biotechnology